Generali Asset Management SPA SGR Boosts Stock Holdings in Royalty Pharma PLC $RPRX

Generali Asset Management SPA SGR grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 7,752.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,081 shares of the biopharmaceutical company’s stock after purchasing an additional 33,647 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Royalty Pharma were worth $1,202,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC increased its holdings in Royalty Pharma by 1.5% during the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 281 shares during the period. Augustine Asset Management Inc. increased its holdings in shares of Royalty Pharma by 4.4% in the 2nd quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 283 shares during the period. GAMMA Investing LLC raised its position in shares of Royalty Pharma by 9.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 289 shares in the last quarter. Merit Financial Group LLC lifted its stake in shares of Royalty Pharma by 3.5% during the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock worth $323,000 after purchasing an additional 306 shares during the last quarter. Finally, Keybank National Association OH boosted its position in Royalty Pharma by 1.0% during the second quarter. Keybank National Association OH now owns 33,139 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 321 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Trading Up 0.6%

Shares of Royalty Pharma stock opened at $38.86 on Monday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 12-month low of $25.40 and a 12-month high of $41.24. The firm has a market capitalization of $22.43 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 1.86 and a beta of 0.43. The firm’s 50 day simple moving average is $38.84 and its two-hundred day simple moving average is $37.12.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. Analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. Royalty Pharma’s payout ratio is currently 66.67%.

Insider Buying and Selling at Royalty Pharma

In other news, EVP George W. Lloyd sold 30,654 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $38.50, for a total value of $1,180,179.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Terrance P. Coyne sold 69,582 shares of Royalty Pharma stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $38.36, for a total value of $2,669,165.52. Following the sale, the chief financial officer directly owned 43,510 shares of the company’s stock, valued at $1,669,043.60. This trade represents a 61.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 846,511 shares of company stock worth $33,011,004. 18.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on RPRX. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price for the company. Cowen reissued a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Morgan Stanley reduced their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Weiss Ratings lowered Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.